Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug
Ovarian cancer is the fifth-leading cause of cancer death among women in the United States.
Eli Lilly and Co.
-
Lilly, IU sign clinical trial, research agreement worth up to $40M
Officials say the pact, facilitated by the Indianapolis-based IU Launch Accelerator for Biosciences, is the largest single industry-sponsored agreement in the school’s history.
Read More -
Lilly, Nvidia team up to build pharma’s ‘most powerful’ supercomputer
The Indianapolis-based drugmaker said the supercomputer will power an “AI factory” designed to accelerate drug discovery and development.
Read More -
Q&A with the head of Lilly manufacturing, who meticulously tracks gains in work, life
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
Read More -
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More
Articles
Popular weight-loss drugs shouldn’t carry suicide warnings, FDA says
U.S. Food and Drug Administration officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs, including Eli Lilly and Co.’s Zepbound, used to treat obesity.
Lilly, Nvidia to establish $1B AI co-innovation lab in San Francisco
The new initiative expands on the massive artificial intelligence supercomputer collaboration the companies announced last fall.
Former GLP-1 users regain lost weight after about 18 months, study says
People who stop taking GLP-1 drugs such as Ozempic, Wegovy and Zepbound for weight loss are projected to regain their shed pounds within about 1-½ years, a review of existing research has found.
Lilly to acquire California-based biopharma company in $1.2B deal
Indianapolis-based Eli Lilly and Co. announced Wednesday it intends to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company developing oral therapies for inflammatory-mediated diseases.
Lilly in talks to buy Ventyx Biosciences for more than $1B, WSJ reports
Ventyx is a San Diego-based biotech that specializes in drugs for inflammatory diseases like Crohn’s and rheumatoid arthritis.
Eli Lilly set to back Aktis Oncology’s upsized $318M IPO
Clinical-stage biotechnology company Aktis Oncology increased the size of its initial public offering by 50% and drew interest from Indianapolis-based Lilly for $100 million of shares in the listing.
First GLP-1 weight-loss pill now available, with pledge of abundant supply
Novo Nordisk is aiming to avoid losing ground to its main rival, Eli Lilly, which is seeking regulatory approval for its own GLP-1 weight-loss pill.
Partnership between public affairs firms highlights growing Indiana-Ireland bond
A former Hoosier lawmaker and a former Irish government minister are linking their firms as Indiana’s ties to Ireland grow.
Indiana attorney general sues Lilly over insulin prices
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
2025 Newsmaker: David Ricks
As of Nov. 13, Eli Lilly and Co.’s market capitalization was $967 billion and flirting with a rare $1 trillion. Its stock price in November surpassed $1,000 per share, up more than 25% for the year.
US regulators approve Wegovy pill for weight loss, giving Novo Nordisk an edge over Lilly
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Lilly’s growth explosion tests state’s workforce development
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
Lilly Phase 3 trial shows GLP-1 pill effective for weight-loss maintenance
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival’s GLP-1 injectable, the Indianapolis-based drugmaker said.
Lilly to build $6B plant in Alabama in 3rd of 4 big US investments
Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
Lilly cuts prices on Zepbound vials sold on LillyDirect
The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.
Lilly rolling out direct-to-employer obesity drug coverage
The Indianapolis-based drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers.
Lilly joins $1 trillion club as weight-loss drugs fuel stock surge
It’s just the latest landmark for Indianapolis-based Lilly, which was catapulted into the top spot as the world’s largest health care company by market capitalization in 2023.
Lilly to open Gateway Labs site in Philadelphia
Since the first biotech incubator site opened in 2019, participating startups have collectively raised more than $3 billion.
The surprising new use for GLP-1s: Alcohol and drug addiction
As GLP-1 drugs for weight loss and diabetes drugs such as Zepbound and Mounjaro generate billions in sales, researchers at Eli Lilly and Co. and other pharma companies are exploring their potential for other purposes.